Syngene, GSK in pact to discover new drugs

Syngene International, a global contract research services company, announced on Monday that it would set up a customised discovery research laboratory along with GSK, a healthcare company.

The multi-year research and development agreement with GSK will focus on accelerating the discovery of new drugs, according to a company statement.

“A team of Syngene scientists will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs,” according to the statement. Syngene started offering discovery services to global research and development focused organisations from 1994. It offers integrated discovery, development and manufacturing services for both the pharmaceutical and biotechnology industries.